Abolition of Aorticorenal Ganglia Pacing Responses Improves Denervation Efficacy
Authors:
- Poornima BalajiPBPoornima Balaji
- Vu Toan TranVTVu Toan Tran
- Michael A. BarryMBMichael A. Barry
- Albert VienAVAlbert Vien
- Edward YangEYEdward Yang
- Duc Minh NguyenDNDuc Minh Nguyen
- Urja PatelUPUrja Patel
- Juntang LuJLJuntang Lu
- Shirley AlvarezSAShirley Alvarez
- Sushil BandodkarSBSushil Bandodkar
- Winny VarikattWVWinny Varikatt
Open Access
- 1 April 2025
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (4) , 680-689
Abstract
BACKGROUND: Transcatheter renal denervation (RDN) remains inconsistent despite developments in ablation technologies, due to the lack of an intraprocedural physiological end point. The aim of this study was to identify if aorticorenal ganglion (ARG) guided RDN using microwave (MW) catheter leads to more consistent denervation outcomes compared with empirical MW ablation. METHODS: Pigs underwent sham procedure (n=8) or bilateral RDN using an in-house built open-irrigated MW catheter. Before denervation, ipsilateral ARG pacing was performed leading to renal artery vasoconstriction. MW ablation group (MW-group; n=7) received 1 ablation (100–120 W for 360 seconds) in the mid-main renal artery based on artery caliber. ARG-guided-MW ablation group (ARG-MW-group; n=7) was permitted an additional ablation more distally or at higher power until a vasoconstrictive response was abolished. Animals were euthanized at 4 to 5 weeks post-procedure. RESULTS: ARG pacing caused an ipsilateral reduction in renal artery caliber from 4.67 to 4 mm; P =0.0006 in MW-group and 4.8 to 3.9 mm; P =0.001 in ARG-MW-group. Repeat ARG pacing at euthanasia led to a reduction in renal artery caliber in MW-group from 5.1 to 4.8 mm; P =0.006, but not in ARG-MW-group from 4.88 to 4.55 mm; P =0.08. There were no differences in ablation injury volumes between the groups. Compared with undenervated sham controls, ARG-MW-RDN versus MW-RDN caused median reductions in viable nerve area (antityrosine hydroxylase staining) at 4 to 5 weeks by 92.6% (interquartile range, 0.94–19.59%; P P =0.006) and median renal cortical norepinephrine content by 68.06% (interquartile range, 27.16–38.39%; P P =NS). CONCLUSIONS: ARG pacing serves as a physiological procedural end point to guide MW denervation to improve denervation outcomes.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trialeClinicalMedicine, 2024
- A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trialsTrends in Cardiovascular Medicine, 2022
- Renal denervation for the treatment of hypertension. Back and strongerRevista Portuguesa de Cardiologia, 2022
- Transvascular Pacing of Aorticorenal Ganglia Provides a Testable Procedural Endpoint for Renal Artery DenervationJACC: Cardiovascular Interventions, 2019
- Renal Denervation Update From the International Sympathetic Nervous System SummitJACC, 2019
- Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trialThe Lancet, 2018
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialThe Lancet, 2017
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysisThe Lancet, 2016
- Methodological Standardization for the Pre-Clinical Evaluation of Renal Sympathetic DenervationJACC: Cardiovascular Interventions, 2014
- Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trialThe Lancet, 2010